<DOC>
	<DOC>NCT00305461</DOC>
	<brief_summary>The aim of the study is to compare the effect of ciclesonide on quality of life, pulmonary function and time to first exacerbation in patients with moderate persistent asthma. Ciclesonide will be administered once daily in the evening at two dose levels. The study duration consists of a baseline period (2 weeks) and a treatment period (8 weeks).</brief_summary>
	<brief_title>Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>Main Written informed consent Good health with the exception of asthma Clinical diagnosis of moderate persistent asthma during the last 6 months prior to visit B0 Pretreatment with inhaled corticosteroids dose equivalent to 250 500 mcg BDP / day at stable dosing during the last 4 weeks prior to visit B0, concomitant or not to shortacting beta2agonists treatment as rescue medication FEV1 ≥ 70% and ≤ 90% predicted measured at least 4 h after the last use of rescue medication at visit B0 Reversibility ≥ 12% and ≥ 200 mL in B0, B0 or T0, after inhalation of 400 mcg of salbutamol Patients compliant to recommended pretreatment Main Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids Chronic obstructive pulmonary disease (COPD) Hospitalization within previous four weeks from baseline Hospitalization due to asthma within the last twelve months Asthma exacerbation within two months previous to baseline History of almost fatal asthma at any moment Pregnancy, breast feeding, intention to become pregnant during the course of the study or lack of safe contraception in premenopausal women Exacerbation of asthma within 2 months prior to entry into the baseline period Use of systemic steroids up to 2 months (injectable depot steroids 6 months) before entry into the baseline period, or more than 3 times during the last 6 months</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Ciclesonide</keyword>
</DOC>